111 related articles for article (PubMed ID: 9397242)
1. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes.
Kawano Y; Matsuoka H; Nishikimi T; Takishita S; Omae T
Am J Hypertens; 1997 Nov; 10(11):1240-4. PubMed ID: 9397242
[TBL] [Abstract][Full Text] [Related]
2. Effect of an intracerebroventricularly administered vasopressin V1 antagonist on blood pressure and heart rate in deoxycorticosterone-salt hypertensive rats.
Toba K; Ouchi Y; Liang J; Akishita M; Orimo H
J Auton Nerv Syst; 1994 Dec; 50(2):123-9. PubMed ID: 7884152
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
[TBL] [Abstract][Full Text] [Related]
4. Effects of vasopressin V1 and V2 receptor antagonists on the development of salt-induced hypertension in Dahl rats.
Hashimoto J; Imai Y; Minami N; Munakata M; Abe K
J Cardiovasc Pharmacol; 1995 Oct; 26(4):548-54. PubMed ID: 8569214
[TBL] [Abstract][Full Text] [Related]
5. Effects of OPC-21268, a vasopressin V1-receptor antagonist, on expression of growth factors from glomeruli in spontaneously hypertensive rats.
Otsuka F; Ogura T; Yamauchi T; Oishi T; Hashimoto M; Mimura Y; Makino H
Regul Pept; 1997 Oct; 72(2-3):87-95. PubMed ID: 9652981
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats.
Sampey DB; Burrell LM; Widdop RE
Am J Physiol; 1999 Mar; 276(3):R872-9. PubMed ID: 10070150
[TBL] [Abstract][Full Text] [Related]
7. Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension.
Crofton JT; Ota M; Share L
J Hypertens; 1993 Oct; 11(10):1031-8. PubMed ID: 8258666
[TBL] [Abstract][Full Text] [Related]
8. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition.
Masaki H; Imaizumi T; Harada S; Momohara M; Hirooka Y; Takeshita A
Am J Physiol; 1993 Jun; 264(6 Pt 2):R1089-94. PubMed ID: 8391757
[TBL] [Abstract][Full Text] [Related]
9. In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260.
Mimura Y; Ogura T; Hayakawa N; Otsuka F; Hashimoto M; Yamauchi T; Makino H; Ogawa N
Nephron; 1997; 76(3):331-6. PubMed ID: 9226235
[TBL] [Abstract][Full Text] [Related]
10. OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats.
Yamada Y; Yamamura Y; Chihara T; Onogawa T; Nakamura S; Yamashita T; Mori T; Tominaga M; Yabuuchi Y
Hypertension; 1994 Feb; 23(2):200-4. PubMed ID: 8307629
[TBL] [Abstract][Full Text] [Related]
11. Enhanced pressor response in spontaneously hypertensive rats induced by stimulation of vasopressin-V1 receptors.
Yamauchi T; Ogura T; Oishi T; Harada K; Hashimoto M; Mimura Y; Asano N; Ota Z; Kageyama J
Acta Med Okayama; 1995 Feb; 49(1):53-9. PubMed ID: 7762410
[TBL] [Abstract][Full Text] [Related]
12. The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats.
Fujita H; Yoshiyama M; Takeuchi K; Omura T; Yamagishi H; Iwao H; Miura K; Yoshikawa J
Jpn J Pharmacol; 1998 Oct; 78(2):229-32. PubMed ID: 9829627
[TBL] [Abstract][Full Text] [Related]
13. Interaction between AVP and sympathetic system in subtotal nephrectomy-saline hypertension: role of alpha and V1 receptors.
Ozaykan B; Doğan A
J Auton Nerv Syst; 2000 Jan; 78(2-3):165-71. PubMed ID: 10789696
[TBL] [Abstract][Full Text] [Related]
14. Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats.
Mimura Y; Ogura T; Yamauchi T; Otsuka F; Oishi T; Harada K; Hashimoto M; Ota Z
Acta Med Okayama; 1995 Aug; 49(4):187-94. PubMed ID: 7502678
[TBL] [Abstract][Full Text] [Related]
15. The effect of chronic guanfacine administration on high plasma vasopressin levels in essential hypertension.
Berkman K; Tözün N; Taga Y; Dedeoğlu A; Onat F; Bekiroğlu N
Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):67-71. PubMed ID: 2407671
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans.
Ohnishi A; Ko Y; Fujihara H; Miyamoto G; Okada K; Odomi M
J Clin Pharmacol; 1993 Mar; 33(3):230-8. PubMed ID: 8385161
[TBL] [Abstract][Full Text] [Related]
17. Baroreflex impairment by low sodium diet in mild or moderate essential hypertension.
Grassi G; Cattaneo BM; Seravalle G; Lanfranchi A; Bolla G; Mancia G
Hypertension; 1997 Mar; 29(3):802-7. PubMed ID: 9052899
[TBL] [Abstract][Full Text] [Related]
18. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
Nishikimi T; Kawano Y; Saito Y; Matsuoka H
J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428
[TBL] [Abstract][Full Text] [Related]
19. Vasopressin V1a receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat.
Fraser TB; Turner SW; Wen C; Li M; Burrell LM; Whitworth JA
Clin Exp Pharmacol Physiol; 2000 Nov; 27(11):866-70. PubMed ID: 11071300
[TBL] [Abstract][Full Text] [Related]
20. Role of vasopressin on cardiovascular changes during hemorrhage in conscious rats.
Fujisawa Y; Miyatake A; Hayashida Y; Aki Y; Kimura S; Tamaki T; Abe Y
Am J Physiol; 1994 Nov; 267(5 Pt 2):H1713-8. PubMed ID: 7977803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
